SG11202108283QA - Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist - Google Patents

Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist

Info

Publication number
SG11202108283QA
SG11202108283QA SG11202108283QA SG11202108283QA SG11202108283QA SG 11202108283Q A SG11202108283Q A SG 11202108283QA SG 11202108283Q A SG11202108283Q A SG 11202108283QA SG 11202108283Q A SG11202108283Q A SG 11202108283QA SG 11202108283Q A SG11202108283Q A SG 11202108283QA
Authority
SG
Singapore
Prior art keywords
triazin
imidazo
amine derivatives
tlr7 agonist
tlr7
Prior art date
Application number
SG11202108283QA
Other languages
English (en)
Inventor
Guoliang Zhang
Jianzhuang Miao
Changyou Zhou
Gang Chen
Jing Li
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of SG11202108283QA publication Critical patent/SG11202108283QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202108283QA 2019-02-07 2020-02-06 Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist SG11202108283QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2019074732 2019-02-07
CN2019098757 2019-07-31
CN2020073673 2020-01-22
PCT/CN2020/074437 WO2020160711A1 (en) 2019-02-07 2020-02-06 Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist

Publications (1)

Publication Number Publication Date
SG11202108283QA true SG11202108283QA (en) 2021-08-30

Family

ID=71947004

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202108283QA SG11202108283QA (en) 2019-02-07 2020-02-06 Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist
SG11202108284TA SG11202108284TA (en) 2019-02-07 2020-02-06 Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202108284TA SG11202108284TA (en) 2019-02-07 2020-02-06 Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist

Country Status (14)

Country Link
US (2) US20230167117A1 (zh)
EP (2) EP3921320B1 (zh)
JP (2) JP2022519374A (zh)
KR (2) KR20210125025A (zh)
CN (2) CN113423708A (zh)
AU (2) AU2020218383A1 (zh)
BR (2) BR112021015016A2 (zh)
CA (2) CA3129234A1 (zh)
IL (2) IL285311A (zh)
MX (2) MX2021009439A (zh)
SG (2) SG11202108283QA (zh)
TW (1) TWI835999B (zh)
WO (2) WO2020160711A1 (zh)
ZA (2) ZA202105339B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3788050A1 (en) 2018-05-01 2021-03-10 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
WO2021023105A1 (zh) * 2019-08-02 2021-02-11 百济神州有限公司 咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物作为tlr8激动剂
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
CN114805392A (zh) * 2021-01-20 2022-07-29 上海维申医药有限公司 大环tlr7激动剂、其制备方法、药物组合物及其用途
IL307600A (en) * 2021-04-09 2023-12-01 Revolution Medicines Inc Synthesis of rapamycin analog compounds
KR20240057402A (ko) * 2021-07-23 2024-05-02 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 그람 음성 박테리아 유출 펌프 억제제
WO2023172347A1 (en) * 2022-03-10 2023-09-14 Nammi Therapeutics, Inc. Formulated and/or co-formulated lipid nanocarriers compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
CN102439011B (zh) * 2009-02-11 2016-05-04 加利福尼亚大学校务委员会 Toll样受体调节剂和疾病的治疗
PE20160217A1 (es) * 2009-09-21 2016-05-18 Gilead Sciences Inc Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
WO2014035140A2 (en) * 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
SG11201701169XA (en) * 2014-08-15 2017-03-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Pyrrolopyrimidine compounds used as tlr7 agonist
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN107849036A (zh) * 2015-05-12 2018-03-27 卡利拉制药公司 二环化合物
US10138248B2 (en) * 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
JP6932394B2 (ja) * 2016-11-11 2021-09-08 ヘポ ファーマスーティカル カンパニー リミテッド 含窒素複素環化合物、製造方法、中間体、医薬組成物及び応用
EP3636646A4 (en) * 2017-05-18 2020-12-09 Jiangsu Hengrui Medicine Co., Ltd. HETEROARYL PYRAZOL DERIVATIVE AND MANUFACTURING METHOD FOR IT AND MEDICAL USES THEREOF

Also Published As

Publication number Publication date
BR112021015012A2 (pt) 2021-10-05
IL285311A (en) 2021-09-30
IL285315A (en) 2021-09-30
AU2020218872A1 (en) 2021-08-26
JP2022521473A (ja) 2022-04-08
EP3921319A1 (en) 2021-12-15
WO2020160710A1 (en) 2020-08-13
JP2022519374A (ja) 2022-03-23
US20220119394A1 (en) 2022-04-21
CA3129178A1 (en) 2020-08-13
MX2021009444A (es) 2021-11-12
BR112021015016A2 (pt) 2021-10-05
EP3921319A4 (en) 2022-11-23
KR20210125025A (ko) 2021-10-15
MX2021009439A (es) 2021-11-12
KR20210125026A (ko) 2021-10-15
EP3921319C0 (en) 2024-03-06
ZA202105339B (en) 2023-02-22
EP3921320A1 (en) 2021-12-15
TW202045507A (zh) 2020-12-16
TWI835999B (zh) 2024-03-21
EP3921320C0 (en) 2024-03-06
CA3129234A1 (en) 2020-08-13
WO2020160711A1 (en) 2020-08-13
SG11202108284TA (en) 2021-08-30
EP3921320B1 (en) 2024-03-06
TW202045508A (zh) 2020-12-16
EP3921319B1 (en) 2024-03-06
CN113423708A (zh) 2021-09-21
AU2020218383A1 (en) 2021-09-02
ZA202105338B (en) 2022-08-31
EP3921320A4 (en) 2022-11-09
US20230167117A1 (en) 2023-06-01
CN113454086A (zh) 2021-09-28

Similar Documents

Publication Publication Date Title
IL285311A (en) Imidazo[1,2-f][4,2,1]triazine-4-amine derivatives as tlr7 agonists
HK1258157A1 (zh) 作為jak抑制劑的吡唑並[1,5-a]吡嗪-4-基衍生物
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
EP4008720A4 (en) IMIDAZO [2,1-F][1,2,4] TRIAZINE-4-AMINE DERIVATIVES AS A TLR8 AGONIST
TWI800696B (zh) 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
IL290419B (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
IL272988A (en) Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors
HUE056561T2 (hu) Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
IL290445A (en) [4,2,1]triazolo[5,1-c]quinazoline-5-amines
ZA202100259B (en) Pyrrolo[1,2-b]pyridazine derivatives
IL280122A (en) Imidazo[2,1-B]pyridazine derivatives as TRK inhibitors
SG11202108648TA (en) 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative
IL279156A (en) History of hexahydropyrrolo[4,3-C]pyrrole useful as LOX inhibitors